Symbols

IRON

Disc Medicine·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 0

Stock Price Surged Significantly

Consensus Rating "Buy"

Ample Liquidity

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IRON

Disc Medicine,Inc.

A clinical stage precision medicine company that developing innovative treatments for genetically-defined age-related macular degeneration

Industry

Biological Technology

Established Date

06/25/2020

Listing Date

08/12/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

155

Fiscal Year Ends

12-31

Website

www.discmedicine.com

Security Type

Common stock

Office address

321 Arsenal Street, Suite 101, Watertown, Massachusetts 02472

Business

Introduction

Disc Medicine, Inc., was incorporated as a Delaware corporation on June 25, 2020. The company is a clinical-stage biopharmaceutical company focused on developing novel therapies for serious blood diseases. Its R&D pipeline targets basic biological pathways in erythropoiesis and function. The main drug candidate bitopertin is being developed for the treatment of erythropoietic porphyria, and other drug candidates target anemia and related diseases.

Company Financials

EPS

IRON has released its 2025 Q4 earnings. EPS was reported at -1.62, versus the expected -1.7, beating expectations. The chart below visualizes how IRON has performed over recent quarters, highlighting trends in earnings surprises.